Premier Biomedical Stock Fundamentals
| BIEI Stock | USD 0.0009 0.0001 10.00% |
Premier Biomedical fundamentals help investors to digest information that contributes to Premier Biomedical's financial success or failures. It also enables traders to predict the movement of Premier Pink Sheet. The fundamental analysis module provides a way to measure Premier Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Premier Biomedical pink sheet.
Premier |
Premier Biomedical Company Shares Outstanding Analysis
Premier Biomedical's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Premier Biomedical Shares Outstanding | 999.98 M |
Most of Premier Biomedical's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Premier Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Premier Biomedical has 999.98 M of shares currently outstending. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The shares outstanding for all United States stocks is 74.88% lower than that of the firm.
Premier Biomedical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Premier Biomedical's current stock value. Our valuation model uses many indicators to compare Premier Biomedical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Premier Biomedical competition to find correlations between indicators driving Premier Biomedical's intrinsic value. More Info.Premier Biomedical is rated below average in return on asset category among its peers. It is rated third in operating margin category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Premier Biomedical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Premier Biomedical's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Premier Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Premier Biomedical's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Premier Biomedical could also be used in its relative valuation, which is a method of valuing Premier Biomedical by comparing valuation metrics of similar companies.Premier Biomedical is currently under evaluation in shares outstanding category among its peers.
Premier Fundamentals
| Return On Asset | -1.54 | |||
| Operating Margin | (22.88) % | |||
| Current Valuation | 1.6 M | |||
| Shares Outstanding | 999.98 M | |||
| Shares Owned By Insiders | 2.36 % | |||
| Price To Earning | 0.07 X | |||
| Price To Sales | 112.03 X | |||
| Revenue | 14.28 K | |||
| Gross Profit | 1.42 K | |||
| EBITDA | 20.91 K | |||
| Net Income | (374.47 K) | |||
| Cash And Equivalents | 71.2 K | |||
| Total Debt | 160.75 K | |||
| Debt To Equity | (1.18) % | |||
| Current Ratio | 0.05 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (344.18 K) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 11 | |||
| Beta | -4.63 | |||
| Market Capitalization | 4.3 M | |||
| Total Asset | 100.94 K | |||
| Retained Earnings | (3.91 M) | |||
| Working Capital | (279.97 K) | |||
| Current Asset | 44.58 K | |||
| Current Liabilities | 324.55 K | |||
| Z Score | -40.0 | |||
| Net Asset | 100.94 K |
About Premier Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Premier Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Premier Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Premier Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. Premier Biomedical, Inc. was founded in 2010 and is headquartered in Jackson Center, Pennsylvania. Premier Biomedical is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Premier Pink Sheet
Premier Biomedical financial ratios help investors to determine whether Premier Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Premier with respect to the benefits of owning Premier Biomedical security.